Transgene (Euronext : TNG)
Transgene is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer.
Financial calendar
- March 27, 2024 - 2023 Fiscal Year Results
- May 14, 2024 - First Quarter 2024 Financial Results
- May 15, 2024 - Annual Shareholders’ Meeting
- September 24, 2024 - First Half 2024 Financial Results
- November 7, 2024 - Third Quarter 2024 Financial Results
Latest press releases
- April 11, 2024 - Availability of Transgene’s 2023 Universal Registration Document
- April 9, 2024 - Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
- March 27, 2024 - Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
Investor Relations Contact
Lucie Larguier, +33 (0)3 88 27 91 00
Key documents
Contact Relations Investisseurs
Lucie Larguier, +33 (0)3 88 27 91 00
Financial information
Key figures
| In € million except share and per share data | 2022 | 2021 | 2020 | 2019 | 2018 |
| Revenue | 10.3 | 17.4 | 9.9 | 13.7 | 42.9 |
| R&D Expense | -32.2 | -32.9 | -27.3 | -31.4 | -27.3 |
| G&A Expense | -7.9 | -7.4 | -6.5 | -7.1 | -7.0 |
| Net income (loss) | -32.8 | -19.5 | -17.2 | -18.8 | 8.0 |
| Net Cash Burn | -22.8 | -10.0 | -17.0 | -20.5 | -24.5 |
| Cash & Cash Equivalents | 26.8 | 49.6 | 26.3 | 43.3 | 16.9 |
| Earnings/Loss per Share (Basic) | -0.33 | -0.21 | -0.21 | -0.23 | 0.13 |
| Earnings/Loss per Share (Diluted) | -0.33 | -0.20 | -0.21 | -0.23 | 0.13 |
| Shares Outstanding | 100,204,071 | 97,771,334 | 83,841,334 | 83,265,464 | 62,275,923 |
Regulated information
Monthly information on shares outstanding and voting rights (in French)
Share buyback program (in French)
Liquidity contract related information
Half-year report on the Transgene liquidity contract
- 2023: at December 31, 2023; at June 30, 2023
- 2022: at December 31, 2022; at June 30, 2022
- 2021: at December 31, 2021; at June 30, 2021
- 2020: at December 31, 2020; at June 30, 2020
- 2019: at December 31, 2019; at June 30, 2019
- 2018: at December 31, 2018; at June 30, 2018
- 2017: at December 31, 2017; at June 30, 2017
- 2016: at December 31, 2016; at June 30, 2016
Chairman’s report on corporate governance and internal controls Statutory Auditors’ fees
Annual General Meeting information
- May 25, 2022: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 26, 2021: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 27, 2020: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 22, 2019: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 23, 2018: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 8, 2017: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 24, 2016: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 11, 2015: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 18, 2014: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
Rights issue
Stock information
General
General
| Stock Market | Euronext Paris – Eurolist (compartiment B) |
| Reuters / Bloomberg | TRNG.PA / TNG.FP |
| ISIN Code | FR0005175080 |
| Total number of shares outstanding | 100,852,742 |
| Initial Public Offering (IPO) | March 26, 1998 |
| Local Sector Index | Next Biotech / CAC Mid 100 |
| Financial Year Ends | December 31 |
Analysts
| Company | Analyst | Phone | |
|---|---|---|---|
| Cantor Fitzgerald | Brandon Folkes | brandon.folkes@cantor.com | +1 212-294-8081 |
| Intron Health | Naresh Chouhan | naresh@intronhealthresearch.com | +44 207 375 9143 |
| Invest Securities | Jamila El Bougrini | jelbougrini@invest-securities.com | +33 (0)1 44 88 88 09 |
| Kempen & Co. | Suzanne van Voorthuizen | suzanne.vanvoorthuizen@kempen.com | +31 (0)20 348 8484 |
| Oddo BHF | Martial Descoutures | martial.descoutures@oddo-bhf.com | +33 (0)1 44 51 85 00 |
Any opinions, forecasts, estimates, projections or predictions regarding Transgene’s performance made by the analysts are theirs alone and do not necessarily represent the opinions, forecasts, estimates, projections or predictions of Transgene or its management. By providing the names of the analysts or certain information from them, Transgene does not imply its endorsement of or concurrence with their reports, conclusions or recommendations. Transgene assumes no liability for the accuracy of such information and undertakes no obligation to update it.
Investor Events & Presentations
Webcasts
- September 20, 2023 - 2023 Half-year results and business update
- May 5, 2023 - New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
- March 16, 2023 - 2022 Full-year results and business update
- September 27, 2022 - Transgene R&D Day (Paris, France)
- November 23, 2021 - TG4050, First positive clinical data from Phase I clinical trials
- November 12, 2020 - Detailed results of the Phase 1b/2 trial of TG4001 and avelumab in advanced HPV-positive cancers presented at SITC 2020
Financial calendar
- March 27, 2024 - 2023 Fiscal Year Results
- May 14, 2024 - First Quarter 2024 Financial Results
- May 15, 2024 - Annual Shareholders’ Meeting
- September 24, 2024 - First Half 2024 Financial Results
- November 7, 2024 - Third Quarter 2024 Financial Results
Investor events
- January 8, 2024 - 13th edition of the LifeSci Advisors Corporate Access Event – January 8 to 10, 2023
- January 15, 2024 - Oddo BHF Forum – January 15 & 16, 2024
- January 30, 2024 - Invest Securities Biomed Forum – January 30, 2024
- April 5, 2024 - Investor Access Event – April 5, 2024
- April 16, 2024 - Van Lanschot Kempen Life Sciences Conference (Amsterdam, Netherlands)- April 16, 2024
- June 6, 2024 - Oddo BHF Nextcap Forum – June 6, 2024
Annual General Meeting
Annual General Meeting of May 15, 2024
2024 ORDINARY AND EXTRAORDINARY MEETING
Location TRANSGENE 400 boulevard Gonthier d’Andernach – Parc d’Innovation 67400 ILLKIRCH-GRAFFENSTADEN – FRANCE
Date and Time 15 May 2024 at 10 am
Documents
